Depressive Disorder, Major
Conditions
Brief summary
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Detailed description
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that adjunctive treatment with seltorexant is superior to placebo in treating depressive symptoms, as measured by change in Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to Day 43 in adult and elderly participants with MDDIS who have had an inadequate response to treatment with a SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (43 days), and a post treatment follow-up phase (7 to 14 days after DB treatment phase). Total duration of study is up to 12 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Interventions
DRUGSeltorexant
Participants will receive Seltorexant tablets.
DRUGPlacebo
Participants will receive matching placebo tablets.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The duration of the current depressive episode must be less than or equal to (\<=) 24 months * Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (\<) 50 percent (%) reduction but with some improvement (that is, improvement greater than \[\>\] 0%) in depressive symptom severity with residual symptoms other than insomnia present, and overall good tolerability, as assessed by the MGH-ATRQ * Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode * Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (\>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is \[ie\], an improvement of \> 20 % on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score \>= 18 at the second screening interview * Have a patient version of the Insomnia Severity Index (ISI) total score \>=15 as well as a clinician version of the ISI total score \>=15 at the second screening visit * Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m\^2) inclusive (BMI=weight/height\^2) * Participant must be medically stable on the basis of clinical laboratory tests performed at screening * Participant must be medically stable on the basis of the following: physical examination (including a brief neurological examination), vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Exclusion criteria
* Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance \[CrCl\] \< 30 milliliter per minute \[mL/min\]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders and uncontrolled Type 1 or Type 2 diabetes mellitus * Has clinically significant hepatic disease as defined by \>=2\*Upper Limit of Normal (ULN) increase of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at screening * Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (\< 25% improvement in symptoms) when treated with an antidepressant of adequate dose (per massachusetts general hospital-antidepressant treatment response questionnaire \[MGH-ATRQ\]) and duration (at least 6 weeks). * Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, or somatoform disorders * Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed * Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Baseline (Day 1), Day 43 | The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score | Baseline (Day 1), Day 43 | The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). Higher scores represented a more severe condition. MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
| Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score | Baseline (Day 1), Day 43 | PROMIS-SD Short Form 8a: static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has 5 options ranged 1 to 5. The direction of responses was not same, sometimes not at all =more sleep disturbance; sometimes not at all =less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores=less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean-50; SD-10. Negative changes in scores=improvement. Higher PROMIS T-score represents more concept measured. Negatively worded (like sleep disturbance), T-score of 60 was one SD worse than average. By comparison, T-score of 40 was one SD better than average. T-score of 50 or above was clinically significant level of sleep disturbance. |
| Change From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score | Baseline (Day 1), Day 43 | The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative changes in MADRS-6 total score indicate improvement. |
| Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43 | At Day 43 | Percentage of participants who achieved response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
| Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score | Baseline (Day 1), Day 43 | The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 was categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement. |
Countries
Argentina, Chile, Denmark, Finland, Malaysia, Poland, Slovakia, South Korea, Ukraine, United States
Participant flow
Pre-assignment details
Participants with major depressive disorder with insomnia symptoms (MDDIS) who had an inadequate response to an ongoing antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) were randomized in the study. Study consisted of screening phase, double-blind (DB) treatment phase and a post-treatment follow-up (FU) phase.
Participants by arm
| Arm | Count |
|---|---|
| Seltorexant During DB treatment phase, participants received seltorexant 20 mg tablet orally once daily from Day 1 to Day 42. Participants were then followed up for safety up to 7 to 14 days after end of DB treatment at Day 43 (up to Day 57) during the follow-up phase. Participants who discontinued study drug prior to Day 35 were encouraged to have additional follow-up visits every 2 weeks until Day 50 to 57. | 107 |
| Placebo During DB treatment phase, participants received placebo matching to seltorexant tablet orally once daily from Day 1 to Day 42. Participants were then followed up for safety up to 7 to 14 days after end of DB treatment at Day 43 (up to Day 57) during the follow-up phase. Participants who discontinued study drug prior to Day 35 were encouraged to have additional follow-up visits every 2 weeks until Day 50 to 57. | 105 |
| Total | 212 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| DB Treatment Phase (Day 1 to Day 43) | Adverse Event | 1 | 6 |
| DB Treatment Phase (Day 1 to Day 43) | Lack of Efficacy | 2 | 5 |
| DB Treatment Phase (Day 1 to Day 43) | Lost to Follow-up | 0 | 1 |
| DB Treatment Phase (Day 1 to Day 43) | Other | 1 | 2 |
| DB Treatment Phase (Day 1 to Day 43) | Protocol Violation | 0 | 1 |
| DB Treatment Phase (Day 1 to Day 43) | Study Terminated by Sponsor | 0 | 1 |
| DB Treatment Phase (Day 1 to Day 43) | Withdrawal by Subject | 2 | 0 |
| Follow-up Phase (Day 44 to Day 57) | Adverse Event | 0 | 1 |
| Follow-up Phase (Day 44 to Day 57) | Other | 1 | 2 |
| Follow-up Phase (Day 44 to Day 57) | Withdrawal by Subject | 0 | 3 |
Baseline characteristics
| Characteristic | Total | Seltorexant | Placebo |
|---|---|---|---|
| Age, Continuous | 49.5 Years STANDARD_DEVIATION 14.12 | 50.2 Years STANDARD_DEVIATION 13.87 | 48.8 Years STANDARD_DEVIATION 14.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 71 Participants | 38 Participants | 33 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 140 Participants | 68 Participants | 72 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 9 Participants | 5 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 23 Participants | 9 Participants | 14 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 3 Participants | 0 Participants |
| Race (NIH/OMB) White | 177 Participants | 90 Participants | 87 Participants |
| Region of Enrollment Argentina | 27 Participants | 13 Participants | 14 Participants |
| Region of Enrollment Chile | 7 Participants | 3 Participants | 4 Participants |
| Region of Enrollment Denmark | 2 Participants | 1 Participants | 1 Participants |
| Region of Enrollment Finland | 19 Participants | 10 Participants | 9 Participants |
| Region of Enrollment Korea, South | 7 Participants | 3 Participants | 4 Participants |
| Region of Enrollment Malaysia | 1 Participants | 1 Participants | 0 Participants |
| Region of Enrollment Poland | 10 Participants | 6 Participants | 4 Participants |
| Region of Enrollment Slovakia | 17 Participants | 9 Participants | 8 Participants |
| Region of Enrollment Ukraine | 48 Participants | 23 Participants | 25 Participants |
| Region of Enrollment United States | 74 Participants | 38 Participants | 36 Participants |
| Sex: Female, Male Female | 161 Participants | 78 Participants | 83 Participants |
| Sex: Female, Male Male | 51 Participants | 29 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 107 | 0 / 105 | 0 / 103 | 0 / 98 |
| other Total, other adverse events | 14 / 107 | 11 / 105 | 0 / 103 | 0 / 98 |
| serious Total, serious adverse events | 0 / 107 | 2 / 105 | 0 / 103 | 0 / 98 |
Outcome results
Primary
Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.
Time frame: Baseline (Day 1), Day 43
Population: The full analysis set 1 (FAS1) included all randomized participants who received at least 1 dose of study intervention in the DB phase and had baseline MADRS total score greater than or equal to (\>=) 24 (per interactive web response system \[IWRS\]). Here 'N' (overall number of participants analyzed) refers to the number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Seltorexant | Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -14.0 Units on a scale | Standard Deviation 10.46 |
| Placebo | Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -13.1 Units on a scale | Standard Deviation 9.51 |
p-value: =0.41195% CI: [-4, 1.64]Mixed Model Repeated Measures (MMRM)
Secondary
Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score
The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 was categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement.
Time frame: Baseline (Day 1), Day 43
Population: FAS1 included all randomized participants who received at least 1 dose of study intervention in the DB phase and had baseline MADRS total score \>=24 (per IWRS). Here 'N' (overall number of participants analyzed) refers to the number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Seltorexant | Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score | -8.8 Units on a scale | Standard Deviation 6.44 |
| Placebo | Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score | -8.1 Units on a scale | Standard Deviation 6.27 |
Secondary
Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score
PROMIS-SD Short Form 8a: static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has 5 options ranged 1 to 5. The direction of responses was not same, sometimes not at all =more sleep disturbance; sometimes not at all =less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores=less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean-50; SD-10. Negative changes in scores=improvement. Higher PROMIS T-score represents more concept measured. Negatively worded (like sleep disturbance), T-score of 60 was one SD worse than average. By comparison, T-score of 40 was one SD better than average. T-score of 50 or above was clinically significant level of sleep disturbance.
Time frame: Baseline (Day 1), Day 43
Population: FAS1 included all randomized participants who received at least 1 dose of study intervention in the DB phase and had baseline MADRS total score \>=24 (per IWRS). Here 'N' (overall number of participants analyzed) refers to the number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Seltorexant | Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score | -13.7 T-score | Standard Deviation 11.06 |
| Placebo | Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score | -11.9 T-score | Standard Deviation 11.83 |
Comparison: In accordance with protocol predefined testing sequence, statistical significance of the primary endpoint was required before testing the second secondary endpoint (PROMIS-SD; Short Form 8a) and thus, a formal statistical testing was not performed.p-value: =0.16795% CI: [-4.87, 0.85]MMRM Model
Secondary
Change From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score
The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative changes in MADRS-6 total score indicate improvement.
Time frame: Baseline (Day 1), Day 43
Population: FAS1 included all randomized participants who received at least 1 dose of study intervention in the DB phase and had baseline MADRS total score \>=24 (per IWRS). Here 'N' (overall number of participants analyzed) refers to the number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Seltorexant | Change From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score | -9.1 Units on a scale | Standard Deviation 6.86 |
| Placebo | Change From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score | -8.1 Units on a scale | Standard Deviation 6.37 |
Secondary
Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). Higher scores represented a more severe condition. MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.
Time frame: Baseline (Day 1), Day 43
Population: FAS1 included all randomized participants who received at least 1 dose of study intervention in the DB phase and had baseline MADRS total score \>=24 (per IWRS). Here 'N' (overall number of participants analyzed) refers to the number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Seltorexant | Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score | -12.0 Units on a scale | Standard Deviation 9.27 |
| Placebo | Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score | -11.3 Units on a scale | Standard Deviation 8.44 |
Comparison: In accordance with protocol predefined testing sequence, statistical significance of the primary endpoint was required before testing the first secondary endpoint (MADRS-WOSI) and thus, a formal statistical testing was not performed.p-value: =0.47395% CI: [-3.41, 1.59]MMRM model
Secondary
Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43
Percentage of participants who achieved response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.
Time frame: At Day 43
Population: FAS1 included all randomized participants who received at least 1 dose of study intervention in the DB phase and had baseline MADRS total score \>=24 (per IWRS).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43 | 42.9 Percentage of participants |
| Placebo | Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43 | 36.3 Percentage of participants |